A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of VARIVAX New Seed Process (NSP) Administered Concomitantly with M-M-R II

Project: Other project

StatusFinished
Effective start/end date4/30/145/1/16

Funding

  • Merck Sharp & Dohme Corporation: $46,846.00